Bristol Myers Squibb Expands CAR T Therapy Breyanzi for MCL Patients
In the TRANSCEND MCL trial, 82.7% of patients responded to Breyanzi, with 71.6% of patients achieving complete response Breyanzi demonstrated sustained clinical benefit, with 50.8% of patients...
